当前位置: X-MOL 学术Ther. Adv. Med. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
Therapeutic Advances in Medical Oncology ( IF 4.3 ) Pub Date : 2019-07-23 , DOI: 10.1177/1758835919862692
Weiqi Xu 1 , Ken Liu 2 , Minjiang Chen 3 , Jin-Yu Sun 4 , Geoffrey W McCaughan 2 , Xiao-Jie Lu 5 , Jiansong Ji 6
Affiliation  

Hepatocellular carcinoma (HCC) notoriously has a poor prognosis. It is currently the fifth most common malignancy and the second leading cause of cancer-related death worldwide.1,2 Current first-line systemic therapy, such as sorafenib, can only extend the overall survival of patients with advanced HCC by 3 months and is associated with significant adverse effects.3 Although HCC is an immunogenic cancer that expresses various tumor associated antigens (TAAs), immune therapies have not demonstrated meaningful efficacy against HCC for decades.4 Interest in immune therapies was recently reinvigorated by the success of a programmed cell death protein 1 (PD-1) blockade observed in the treatment of advanced melanoma first reported in 2010.5 Since then, several monoclonal antibodies directed against the immune inhibitory molecules PD-1, programmed cell death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), have been trialed, with promising antitumor immune responses seen against many solid tumors from bench to bedside.

中文翻译:

肝细胞癌的免疫治疗:最新进展和未来展望

众所周知,肝细胞癌(HCC)的预后很差。目前,它是全球第五大常见恶性肿瘤,也是癌症相关死亡的第二大原因。1,2目前的一线全身治疗,如索拉非尼,只能将晚期 HCC 患者的总生存期延长 3 个月,并且伴有显着的不良反应。3尽管 HCC 是一种表达多种肿瘤相关抗原 (TAA) 的免疫原性癌症,但免疫疗法几十年来尚未证明对 HCC 具有有意义的疗效。4最近,由于在 2010 年首次报道的晚期黑色素瘤治疗中观察到的程序性细胞死亡蛋白 1 (PD-1) 阻断的成功,人们对免疫疗法的兴趣重新燃起。5 此后,几种针对免疫抑制分子 PD 的单克隆抗体出现-1、程序性细胞死亡配体 1 (PD-L1) 和细胞毒性 T 淋巴细胞相关抗原 4 (CTLA-4) 已经过试验,从实验室到临床,都对许多实体瘤产生了有希望的抗肿瘤免疫反应。
更新日期:2019-07-23
down
wechat
bug